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ABSTRACT 
 
Researchers have identified several methods for treating acute myocardial 
infarction (AMI) patients affected by ischemia and reperfusion injury. Some of 
these therapies include thrombolysis, balloon angioplasty, and coronary arterial 
bypass graft (CAGB). This lab has previously demonstrated that transplantation 
of mitochondria into the ischemic zone of a rabbit heart during reperfusion 
significantly improved recovery as compared to current techniques. In order for 
this therapy to be translated into the clinic a rapid isolation method for producing 
highly pure and functional mitochondria will be required.  
Previously described mitochondrial isolation methods using differential 
centrifugation and/or Ficoll gradient centrifugation require 60 to 100 minutes to 
complete. Herein, a method for rapid isolation of mitochondria from mammalian 
tissue biopsies is described. In this protocol, manual homogenization is replaced 
 vi 
with the tissue dissociator’s standardized homogenization cycle. This allows for 
uniform and consistent homogenization of tissue that is not easily achieved with 
manual homogenization. Following tissue dissociation, the homogenate is filtered 
through nylon mesh filters which eliminates repetitive centrifugation steps. 
Mitochondrial isolation time is less than 30 minutes compared to 60-100 minutes 
using alternative methods. This isolation protocol yields approximately 2 x 1010 
viable and respiration competent mitochondria from 0.18 ± 0.04 g (wet weight) 
tissue sample. 
 vii 
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INTRODUCTION 
History of Mitochondria  
Mitochondria were first identified back in the 18th century1. Since this initial 
discovery, scientists have worked to gain a greater understanding of 
mitochondrial form and function. Cytologists discovered the ultrastructure of the 
mitochondria. Biochemists identified mitochondria as the location for cellular 
respiration. Molecular biologists discovered that mitochondria have their own 
deoxyribonucleic acid (DNA). And, physiologists uncovered the mechanisms 
involved in mitochondrial functions which include adenosine triphosphate (ATP) 
production, apoptosis and calcium signaling 1.     
Mitochondria are found in every cell of the body except red blood cells and 
are responsible for producing more than 90% of the body’s energy2-6. When 
mitochondria do not function properly, energy production is significantly reduced 
which can lead to cell injury, cell death, and sometimes system failure2. 
Consequently, mitochondria have recently become an important focus for 
researchers exploring the role of mitochondrial dysfunction in disease. These 
studies have been performed using mitochondria isolated from numerous tissues 
and cells derived from both healthy samples as well as disease models. 
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Mitochondria and Disease 
Mitochondrial mutations often result in oxidative phosphorylation 
(OXPHOS) dysfunction. Because OXPHOS is vital for cell survival, these 
mutations result in cellular dysfunction and in some cases cell death7.  These 
mutations are thought to play a role in several diseases. Organs like the brain 
and heart suffer immensely from mitochondrial mutations because they rely 
heavily on oxidative function5. Researchers have recently been exploring the role 
of mitochondrial dysfunction in neurological disorders including Parkinson’s, 
Huntington’s and Alzheimer’s disease8,9. In addition, the role of mitochondrial 
dysfunction in cancer is being explored10-12. Other researchers are investigating 
the detrimental effects mitochondrial dysfunction can have on the heart. This lab 
and others have explored the role of mitochondrial damage in the heart during 
ischemia and reperfusion13-17.  
Mitochondrial Damage Caused by Ischemia and Reperfusion 
Reperfusion is a major cause of myocardial cell damage following AMI. 
Reperfusion induces a number of cellular abnormalities including a large influx of 
calcium, reduced ATP production, an increase in reactive oxygen species (ROS), 
and a loss of membrane phospholipids18. Due to inflammation, leucocyte 
migration, and cellular swelling, hemorrhage is common in the myocardium after 
reperfusion19. In the most current research, particular attention has been placed 
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on the damage suffered by mitochondria. Mitochondrial insults that result from 
reperfusion include a change in volume, a change in oxidative phosphorylation, 
and a change in calcium content16. Additionally, ROS contribute to mitochondrial 
injury by inducing the opening of the mitochondrial permeability transition pore 
(mPTP). The opening of this pore leads to cell death and contributes to infarct 
size in patients suffering from AMI18. These mitochondrial impairments are 
thought to be a major reason many AMI patients have a poor recovery16.  
Clinical Treatments 
Researchers have identified many methods for treating AMI patients 
affected by reperfusion injury. Some of these therapies include thrombolysis, 
balloon angioplasty, and CAGB19. One ischemic post conditioning therapy entails 
interrupting reperfusion with a slightly inflated angioplasty balloon that obstructs 
the coronary artery. This therapy has had success in reducing the size of the 
infarct. This success, however, is limited to patients fitting certain criteria20. A 
different study suggested that primary percutaneous coronary intervention (PCI) 
was the best method to reduce reperfusion injury and improve patient recovery21. 
Although many of these therapies have been useful in reducing injury caused by 
myocardial reperfusion, researchers acknowledge that there are still many 
obstacles that need to be overcome including the large cost for developing new 
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therapies, and the transition of the utilization of treatments used in animal models 
to humans22.  
Despite these difficulties, investigators are continuing to propose novel 
techniques because current AMI treatments have not eliminated all patient 
complications. Some of these more recent techniques involve transplantation of 
pharmacologic therapeutic agents into the infarcted zone of the myocardium in 
an attempt to regenerate damaged tissue16. However, once again the success is 
limited. One particular approach being pursued by this lab is transplantation of 
healthy mitochondria into the myocardium just prior to reperfusion17. In order for 
investigators to fully explore this technique’s therapeutic potential in humans, a 
clinically oriented mitochondrial isolation procedure will be required. 
Isolation of Mitochondria 
The earliest published accounts of mitochondrial isolation date to the 
1940s1,23-25. The first documented attempt demonstrated mitochondrial isolation 
by grinding liver tissue in a mortar followed by centrifugation in a salt solution at 
low speed1,23. Later, other groups expanded upon the original procedure and 
demonstrated tissue fractionation based on differential centrifugation1,24-25. These 
early methods formed the basis of current techniques which often incorporate 
homogenization, and/or differential centrifugation26-32. The number of 
homogenization and centrifugation steps varies among protocols. These 
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repetitive steps increase the time for mitochondrial isolation and ultimately 
reduce viability. In addition, manual homogenization can cause mitochondrial 
damage and inconsistent results if not properly controlled27,33. Thus, a more 
standardized and rapid mitochondrial isolation method would greatly benefit 
researchers exploring the potential of mitochondrial therapy in the clinic. 
Objectives 
To greater meet the requirements for clinical utilization a rapid 
mitochondrial isolation procedure has been developed that utilizes standardized 
tissue dissociation followed by differential filtration. Recently, homogenization 
and differential centrifugation was used to isolate mitochondria for transplantation 
into myocardial tissue16,17. This lengthy isolation procedure required 
approximately 90 minutes and the clinical applicability of this method was 
therefore limited. To allow for acute therapeutic use in clinical and surgical 
treatment a rapid mitochondrial isolation procedure has been developed that can 
be performed in less than 30 minutes.   
The major benefits of this protocol are that standardized tissue 
dissociation allows for uniform and consistent homogenization of tissue that is 
not easily achieved with manual homogenization. In addition, the use of 
differential filtration in place of differential centrifugation eliminates time-
 6 
consuming and repetitive centrifugation steps allowing for more rapid isolation of 
highly purified, viable and respiration competent mitochondria.  
It is hypothesized that the ability to isolate viable and respiration 
competent mitochondria in less than 30 minutes will allow for clinical applicability. 
This isolation protocol has potential for use in coronary arterial bypass grafting 
surgery (CABG) and other therapeutic procedures.  
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METHODS 
Preparation of Solutions 
Several stock solutions were prepared including: 1 M K-HEPES (pH 7.2), 
0.5 M K-EGTA (pH 8), 1 M KH2PO4, and 1 M MgCl2.  
10X Phosphate Buffered Saline (PBS) was prepared by weighing 80g of 
NaCl, 2g of KCl, 14.4g of Na2HPO4, and 2.4g of KH2PO4 into 1 L double distilled 
H2O (pH 7.4).  
1X PBS was prepared by transferring 100 mL of 10X PBS into 900 mL of 
double distilled H2O.  
Homogenizing buffer (pH 7.2) containing 300 mM sucrose, 10 mM K-
HEPES, and 1 mM K-EGTA was prepared. The homogenizing buffer was stored 
at 4 oC.  
Respiration buffer containing 250 mM sucrose, 2 mM KH2PO4, 10 mM 
MgCl2, 20 mM K+-HEPES buffer (pH 7.2) and 0.5 mM K+-EGTA (pH 8.0) was 
prepared. The respiration buffer was stored at 4 oC. 
Subtilisin A stock solution was prepared by weighing 4 mg of Subtilisin A 
into a 1.5 mL microfuge tube which was stored at -20 oC until use. Immediately 
prior to the mitochondrial isolation, Subtilisin A was dissolved in 1 mL of 
homogenizing buffer. Bovine Serum Albumin (BSA) stock solution was prepared 
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by weighing 20 mg of BSA into a 1.5 mL microfuge tube which was stored at -20 
oC until use. Immediately prior to the mitochondrial isolation, BSA was dissolved 
in 1 mL of homogenizing buffer.  
Animals 
All experimentation was approved by the Institutional Animal Care and 
Use Committee at Harvard Medical School and conformed to the National 
Institutes of Health (NIH) guidelines regulating the care and use of laboratory 
animals (NIH Publication No. 5377-3, 1996). All research was performed in 
accordance with the American Physiological Society’s Guiding Principles in the 
Care and Use of Animals.  
Mitochondrial Isolation 
Liver and skeletal muscle was excised from a female Lewis rat and each 
was stored in a 50 mL conical tube filled with 1X PBS at 4 oC. Tissue samples 
were removed to a pre-chilled petri dish and trimmed of any fat and connective 
tissue using sterilized forceps and scissors. The tissue was washed in ice cold 
homogenizing buffer 3 X.   
Next, six mitochondrial samples were prepared from each tissue using a 
6mm biopsy punch (Miltex, York, PA). Each sample consisted of two 6mm biopsy 
punches. The samples were transferred to a gentleMACS dissociation C tube 
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(Miltenyl Bitoec, Auburn, CA) containing 5 mL of ice cold homogenizing buffer. 
Samples were then homogenized via the gentleMacs tissue dissociator’s 
(Miltenyl Biotec, Auburn, CA) standardized 60 second cycle. The dissociation C 
tube was removed to an ice bucket and 250 µL of Subtilisin A stock solution was 
added to the homogenate and mixed by inversion. The C tube was incubated on 
ice for ten minutes.  
A 40 µm filter (BD, Franklin Lakes, NJ) was placed onto a 50 mL conical 
tube and pre-wet with homogenizing buffer. The buffer was discarded from the 
tube and the homogenate was filtered into a new 50 mL conical tube. At this 
point 250 uL of BSA stock solution was added to the filtrate and the homogenate 
was mixed by inversion. Next, a 40 µm filter was placed onto a 50 mL conical 
tube and pre-wet with homogenizing buffer. The buffer was discarded from the 
tube and the homogenate was filtered into the 50 mL conical tube. This step was 
repeated using a 10 µm filter (pluriSelect, San Diego, CA).  
The filtrate was then transferred to two pre-chilled 1.5 mL eppendorf tubes 
and centrifuged at 9000 x g for ten minutes at 4 oC. The supernatant was 
removed and the pellets were combined and re-suspended in about 1 mL of ice-
cold respiration buffer. An outline of the procedural steps in the isolation of 
mitochondria using tissue dissociation and differential filtration is shown in Figure 
1. Total procedural time was less than 30 minutes.  
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Figure 1 –Schema for the isolation of mitochondria using tissue 
dissociation and differential filtration. A: Transfer two 6 mm biopsy sample 
punches to 5 mL of Homogenizing Buffer in a dissociation C tube and 
homogenize the samples using the tissue dissociator’s 1 minute homogenization 
program. B: Add 250 µL Subtilisin A stock solution to the homogenate in the 
dissociation C tube and incubate on ice for 10 minutes. C: Filter the homogenate 
through a pre-wetted 40 µm mesh filter in a 50 mL conical centrifuge tube on ice 
and then add 250 µL of BSA stock solution to the filtrate. D: Re-filter the filtrate 
through a new pre-wetted 40 µm mesh filter in a 50 mL conical centrifuge on ice. 
E: Re-filter the filtrate through a new pre-wetted 10 µm mesh filter in a 50 mL 
conical centrifuge tube on ice. F: Transfer the filtrate to 1.5 mL microfuge tubes 
and centrifuge at 9000 x g for 10 minutes at 40C. G: Remove the supernatant 
and re-suspend and combine the mitochondrial pellets in 1 mL Respiration 
Buffer. Total procedure time is less than 30 minutes. 
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ATP Luminescence Assay 
In order to determine the metabolic activity of isolated mitochondria, an 
ATP luminescence assay was performed using the ATPlite Luminescence 1000 
assay system (Perkin Elmer, Billerica, MA). All reagents and standards were 
supplied in the assay kit. The assay was performed according to the 
manufacturer’s instructions. A summary of the procedure is as follows: Kit 
reagents were equilibrated to room temperature. A 10 mM ATP stock solution 
was prepared by dissolving a lyophilized ATP pellet in 1,170 µL of double distilled 
water. The ATP standard stock solutions and prepared mitochondrial samples 
were stored on ice.  5 mL of substrate buffer solution was added to a vial of 
lyophilized substrate solution. This solution was mixed gently and placed in the 
dark. Next, 100 µL of Respiration Buffer was added to all wells of a black, 
opaque bottom, 96 well plate (VWR). Then, 10 µL of mitochondria from each of 
the six prepared samples was added to the appropriate wells. Note: Samples 
were plated in triplicate. The top row of the plate was left empty for the standards 
and 10 uL of Respiration Buffer was added to the last three wells for the negative 
control as indicated on the plate map (Figure 2). Next, 50 µL of mammalian cell 
lysis solution was added to all wells, including standards and controls. The plate 
was incubated at 37 ˚C for 5 minutes on an orbital shaker (Heidolf, Germany) at 
125 rpm. During the incubation ATP standards in concentrations of 0.1 mM, 0.05 
mM, 0.01 mM, 0.005 mM, 0.001 mM, and 0.0001 mM ATP were prepared from 
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the 10 mM ATP stock solution. Standards were stored on ice. Following the 
incubation, 10 uL of ATP standards were added to corresponding wells as 
indicated on the plate map. Note: Standards were performed in duplicate (Figure 
2). Then, 50 µL of the reconstituted substrate solution was added to each well. 
Again, the plate was incubated at 37 ˚C on the orbital shaker for 5 minutes at 125 
rpm.  
The luminescence of each well was recorded using Gen5 1.11 (BioTek) 
software on a computer linked with a Synergy H4 multi-mode microplate reader 
(BioTek, Winooski, VT). Settings were adjusted as follows: Read type: Endpoint, 
Integration Time: 0:01.00 MM:SS.ss, Filter Sets: 1, Emission: Hole, Optics 
Position: Top, Sensitivity: 100, Top Probe Vertical Offset: 1.00 mm. When the 
plate was ready to be analyzed, it was placed into the tray with well A1 in the 
upper left corner. A standard curve was calculated from which the unknown 
mitochondrial ATP content was determined. Note: Higher values correlate with 
increased ATP levels and higher metabolic activity. 
 13 
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Figure 2- Plate map for ATP assay. This plate map illustrates how to set up 
standards (A1-A12), mitochondria samples (B1-C6), and negative controls (C7-
C9) for the ATP assay. During the assay, 100 µL of Respiration Buffer, 50 µL of 
mammalian cell lysis solution and 50 µL of reconstituted substrate solution are 
added to all wells (A1-C9). 
Assessment of Mitochondrial Yield  
Mitochondria preparations were quantified using a Bicinchoninic Acid 
(BCA) protein assay as described by Smith et al34. Mitochondria preparations 
were counted with the Beckman Coulter Counter 4 (Beckman Coulter, Danvers, 
MA).  To allow for comparison mitochondrial number was also determined by 
hemocytometer (Fisher Scientific, Pittsburg, PA).  
Assessment of Mitochondrial Viability  
 Mitochondria were stained with MitoTracker Red CMXros (Invitrogen, 
Carlsbad, CA) as previously described16,17. Mitochondrial purity was determined 
by transmission electron microscopy (TEM) as previously described 16,17. 
Mitochondrial respiration was assessed using a Clark type electrode as 
previously described16,17.   
 
 
 
 
 
 15 
RESULTS 
Tissue samples obtained using a 6 mm biopsy punch weighed 0.18 ± 0.04 
g (wet weight). The number of mitochondria isolated as determined by particle 
size counting was  2.4 x 1010  ± 0.1 x 1010 mitochondria for skeletal muscle and 
2.75 x 1010  ± 0.1 x 1010 mitochondria for liver preparations (Figure 3A). 
Mitochondrial number was underestimated as determined by hemocytometer as 
0.11 x 1010 ± 0.04 x 1010 mitochondria for skeletal muscle and 0.34 x 1010 ± 0.09 
x 1010 mitochondria for liver preparations (Figure 3A).  
Mitochondrial diameter as determined by size based particle counter is 
shown in Figure 3B. The representative tracing shows the isolated mitochondria 
are localized under one peak with mean diameter of 0.38 ± 0.17 µm in 
agreement with previous reports25. 
Mitochondrial protein/ g (wet weight) starting tissue as determined by BCA 
assay was 4.8 ± 2.9 mg/g (wet weight) and 7.3 ± 3.5 mg/g (wet weight) for 
skeletal muscle and liver samples respectively (Figure 3C).  
Mitochondrial purity was determined by TEM and is shown in Figure 3D. 
Mitochondria are shown to be electron dense with less than 0.01% being 
fractured or damaged. Contamination by non-mitochondrial particles was less 
than 0.001%. 
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Figure 3 – Mitochondrial yield and purity. A: Hemocytometer and particle size 
counter mitochondria number isolated from 0.18 ± 0.04 g tissue (wet weight) for 
skeletal muscle and liver. B: Mitochondrial size distribution as detected by 
particle size counter. C: Mitochondrial protein mg/g tissue wet weight for skeletal 
muscle and liver. D: Transmission electron microscopy image of isolated 
mitochondria. Scale bar is 100 nm. Arrows indicate possible contamination by 
non mitochondrial particles and damaged mitochondria. 
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Mitochondrial viability was determined by MitoTracker Red as previously 
described16,17. Results indicate that the isolated mitochondria are intact and able 
to maintain membrane potential (Figure 4A-C). 
ATP was determined using a luminescent assay kit. A plate map for the 
ATP assay is shown in Figure 2. ATP standards were plated in duplicate. 
Mitochondrial samples and negative controls were plated in triplicate. ATP 
content was 10.67± 4.38 nmol/mg mitochondrial protein and 14.83 ± 4.36 
nmol/mg mitochondrial protein for skeletal muscle and liver samples respectively 
(Figure 4D).  
Mitochondrial oxygen consumption rate was 178 ± 17 nM O2/min/mg 
mitochondrial protein for skeletal muscle and 176 ± 23 nM O2/min/mg 
mitochondrial protein for liver preparations. Respiratory control index (RCI) 
values were 2.45 ± 0.34 and 2.67 ± 0.17 for skeletal muscle and liver sample 
preparations respectively (Figure 4E). These results are similar to those reported 
in previous studies using manual homogenization and differential centrifugation 
to isolate mitochondria16-17.  
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Figure 4 – Mitochondrial viability. Representative photomicrographs of isolated 
mitochondria A: under phase contrast illumination and B and C: under 
fluorescence, with mitochondria labeled with MitoTracker Red CMXRos. Scale 
bars are 25 µm (A,B) and 5 µm (C). These images indicate that mitochondria 
maintained membrane potential. D: ATP content nmol/mg mitochondrial protein 
as determined by ATP assay and E:  RCI (state 3 / state 4) as determined by 
Clark electrode. 
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DISCUSSION 
To successfully isolate mitochondria using this protocol it is essential to 
keep all solutions and tissue samples on ice to preserve mitochondrial viability. 
Even when maintained on ice, isolated mitochondria will exhibit a decrease in 
functional activity over time35.  It is recommended that all solutions and additions 
be pre-prepared. Subtilisin A is pre-weighed and stored in 4 mg aliquots in 1.5 
mL microfuge tubes and stored at -20 oC. Similarly BSA is pre-weighed and 
stored in 20 mg aliquots in 1.5 mL microfuge tubes that can be stored at -20 oC . 
Just prior to use the tubes are removed from -20 oC and dissolved in 1 mL of 
homogenizing buffer for use in the mitochondrial isolation procedure.  
Two biopsy punches from mammalian tissue obtained using a 6 mm 
biopsy punch provide sufficient mitochondria for use in clinical and surgical 
procedures for therapeutic interventions16-17. In past studies, tissue samples of a 
similar size provided enough mitochondria to improve recovery in an ischemic 
rabbit heart16-17. To estimate mitochondrial number this lab has used two 
methods, hemocytometer and particle size counting. The use of particle size 
counting is recommended. The Beckman Coulter Counter 4 uses electrical 
impedance to measure the volume of particles passing through an aperture of a 
defined size. The particle size counter is costly but provides accurate and reliable 
estimates and is user independent. Mitochondrial number can be measured more 
cheaply using a hemocytometer. This lab’s studies have demonstrated that this 
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method provides variable estimates that are approximately one order of 
magnitude less than that obtained using a particle size counter. It has also been 
noted that counts obtained by hemocytometer are highly dependent on the user. 
To ensure consistent estimates all counts using a hemocytometer should be 
performed by one person.  
One advantage of this mitochondrial isolation technique is that extra 
filtration steps are utilized to ensure the isolated mitochondria are of high quality 
and purity. Digital images of mitochondria preparations that were filtered through 
two 40 µm filters only and preparations that were filtered through two 40 µm 
filters and one 10 µm filter were taken (Figure 5). All mitochondria preparations 
appeared relatively clean but preparations filtered an additional time through a 10 
µm filter were considerably cleaner. Although filtration is highly effective it can be 
difficult to filter the homogenate through the filters because cellular debris can 
clog up the pores. It is helpful to slowly pipette the homogenate through the first 
filter into a new conical tube. If the filter becomes blocked with cellular debris, 
change the filter. For the next filtration simply pour the filtrate through a new 40 
µm filter into a new conical tube. 
 
 
 21 
 
 
Figure 5- Digital Microscope 20x phase images of mitochondria 
preparations. A) Liver mitochondria preparation filtered through two 40 µm 
filters. B) Liver mitochondria preparation filtered through two 40 µm filters plus 
one 10 µm filter. C) Skeletal muscle mitochondria preparation filtered through two 
40 µm filters. D) Skeletal muscle mitochondria preparation filtered through two 40 
µm filters plus one 10 µm filter. Scale bar = 50 µm. 
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This lab has found ATP assay kits to be useful for determining 
mitochondrial function. The kit supplies all necessary reagents and provides a 
simple and fast method for determining the metabolic activity of isolated 
mitochondria. The ATP assay provides similar results as those obtained using a 
Clark type electrode and therefore is compatible with previous data analysis36-37. 
This method for rapid isolation of mitochondria using tissue dissociation 
and differential filtration provides an isolation time frame compatible for clinical 
and surgical therapeutic intervention16-17. A major advantage of this mitochondrial 
isolation protocol is that it allows for isolation of a high yield of viable, respiration 
competent mitochondria free of contamination in less than 30 minutes.  
Differential filtration in place of differential centrifugation significantly reduces 
procedure time.  Other protocols incorporate several centrifugation steps with 
overall isolation time being 60 minutes to 100 minutes16-17,30-33. Another 
advantage of this protocol is that tissue homogenization is standardized. The 
commercial tissue dissociator provides a standardized cycle and yields 
consistent and reproducible results. This is in contrast to manual homogenization 
that is subject to user variability and inconsistency.  
Because tissue dissociation is achieved in a closed system, the sample 
preparation has a better chance of remaining sterile than a sample prepared 
using manual homogenization. Sterilizing all solutions prior to performing the 
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isolation and using only sterilized materials, equipment, tools, etc. makes this 
procedure even more clinically relevant.  
Transplanted mitochondria have great potential to improve AMI patient 
recovery by providing cardioprotection and enhancing post ischemic function. 
 Transplanted mitochondria are taken up by cells as early as two hours post 
transplantation16-17. Once inside the cell, transplanted mitochondria augment 
ATP levels and maintain viability16-17. Another significant finding of this lab is that 
transplanted mitochondria do not induce an immune response. Post 
mitochondrial injection, serum samples can be analyzed using ELISA, indirect 
immunofluorescence and a multiplex (42-plex) assay 16,17. Transplantation of 
mitochondria does not induce inflammation, an auto-immune response or 
upregulation of chemokines/cytokines16-17. This finding makes the possibility of 
using transplanted mitochondria as a treatment for AMI patients even more 
probable. 
In addition, transplantation of mitochondria into the ischemic zone of the 
myocardium results in increased ATP production, upregulation of proteins 
associated with mitochondrial complexes, and upregulation of cytokines16-17.  
Upregulated cytokines are those associated with angiogenesis, 
immunomodulation, arteriogenesis, prevention of apoptosis, progenitor cell 
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migration, and enhanced cell salvage. These cytokines improve post ischemic 
recovery by decreasing necrosis and apoptosis16-17.  
This technique can be used in the clinic alone or in conjunction with 
current therapies to improve patient outcomes. Although all prior experimentation 
was done in animals, this lab is hopeful that this treatment will have the same 
effects in humans. 
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